Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc reports news on a hub-and-spoke biotherapeutics model built around internal programs and Founded Entities. Recurring updates cover portfolio strategy, annual and half-year results, capital allocation, and clinical development across medicines for inflammatory, immunological, oncologic, gastrointestinal, neurological and neuropsychiatric disorders.
Company news frequently includes deupirfenidone for idiopathic pulmonary fibrosis, LYT-200, a fully human anti-galectin-9 monoclonal antibody for myeloid malignancies, and Seaport Therapeutics programs using the Glyph platform for oral neuropsychiatric medicines. Other developments include scientific publications, clinical data releases, board and leadership changes, shareholder voting matters and capital-structure disclosures tied to PureTech and its Founded Entities.
Vedanta Biosciences, a clinical-stage biopharmaceutical company, announced that Bernat Olle, CEO, will present at the 9th International Human Microbiome Consortium Congress in Kobe, Japan from November 8-10, 2022. The presentation, titled Development of a Defined Bacterial Consortium for the Prevention of Recurrent Clostridioides Difficile Infection, will showcase Phase 2 results of VE303, a therapeutic candidate for preventing recurrent Clostridioides difficile infection, which showed a 31.7% absolute risk reduction in recurrence compared to placebo.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced participation in the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 12:50pm PST / 3:50pm EST. Executives Bharatt Chowrira, Ph.D., J.D., and Julie Krop, M.D., will engage in a fireside chat. The event will be webcast at investors.puretechhealth.com. PureTech is focused on innovative biotherapeutics, boasting a diverse pipeline of 27 therapeutic candidates, including FDA-cleared products.
PureTech Health plc (LSE:PRTC, Nasdaq:PRTC) has announced that its CEO, Daphne Zohar, and CMO, Julie Krop, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York City on September 14, 2022, at 2:05 PM EDT. The event will be available via webcast at investors.puretechhealth.com. PureTech continues to advance its extensive pipeline of 27 therapeutics, with some achieving FDA clearance and European marketing authorization.
PureTech Health announced that data from a Phase 1 crossover trial of LYT-100 indicates improved tolerability compared to pirfenidone, supporting dose selection for the Phase 2 trial in patients with idiopathic pulmonary fibrosis (IPF). The Phase 1 trial showed a 50% reduction in gastrointestinal adverse events and a 45% reduction in nervous system treatment-emergent adverse events. The Phase 2 trial, aimed at establishing safety and efficacy, initiated in June 2022. LYT-100, a deuterated form of pirfenidone, is expected to improve patient compliance and outcomes.
PureTech Health plc announces a multi-year partnership with Koye Pharmaceuticals to develop a vocal biomarker for chronic obstructive pulmonary disease (COPD) in India. This collaboration represents Sonde Health's first agreement with a pharmaceutical firm. Utilizing Sonde's vocal biomarker platform, the aim is to enhance monitoring and treatment of COPD patients through voice technology. COPD is a significant health issue in India, accounting for 13% of deaths. The partnership seeks to leverage advanced technology to improve patient outcomes.
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) is set to announce its half-yearly results for the six months ending June 30, 2022, on August 25, 2022. The Company will host a presentation and conference call for analysts and shareholders at 9:00 am EDT. PureTech is focused on developing innovative therapeutics for serious diseases, boasting a diverse pipeline of 27 therapeutic candidates, including two with FDA clearance and European marketing authorization.
PureTech Health's Founded Entity, Akili Interactive Labs, has launched a pivotal Phase 3 study of SDT-001, a digital treatment aimed at improving attention in children with ADHD in Japan. This trial follows a successful Phase 2 study showing enhanced attention compared to standard treatments. Approximately 150 participants aged 6-17 will enroll in multiple sites, with results expected in 2H2023. The treatment leverages video game technology designed to engage cognitive functions. Akili's products are already FDA-cleared and CE-marked in the U.S. and Europe for similar indications.
PureTech Health plc (Nasdaq: PRTC) reported positive results from a study of Akili's digital therapeutic AKL-T01 for cognitive dysfunction in patients with Systemic Lupus Erythematosus (SLE). Conducted with 60 participants, the study showed significant improvements in motor speed and executive functions. The EVO™ Monitor also demonstrated its potential for rapid mobile cognitive assessment. This technology could enhance treatment options for approximately 1.5 million SLE patients in the U.S., where cognitive dysfunction affects 20% to 80% of them.
PureTech Health (LSE: PRTC, Nasdaq: PRTC) announced nominees for the board of directors for its Founded Entity, Akili Interactive, following its merger with Social Capital Suvretta Holdings Corp. I (Nasdaq: DNAA). The board will include industry leaders such as BJ Jones, Christine Lemke, Ken Ehlert, and Chamath Palihapitiya, who bring extensive experience in biopharmaceuticals and healthcare. This move marks a significant step toward Akili’s goal of scaling digital therapeutics, particularly as it approaches market introduction of its first product.
Vedanta Biosciences, a clinical-stage biopharmaceutical company, has announced participation in two upcoming investor conferences: the William Blair Biotech Focus Conference on July 12-13, 2022, in New York, and the SVB Securities Biopharma Private Company Connect on July 20-21, 2022, offering virtual 1x1 meetings. The company specializes in pioneering oral therapies using defined bacterial consortia, targeting conditions such as C. difficile infection, inflammatory bowel diseases, and cancer. Vedanta boasts over 45 patents and a vast library of bacteria from the human microbiome.